242 related articles for article (PubMed ID: 29680151)
1. VMAT2 Inhibitors and the Path to Ingrezza (Valbenazine).
Harriott ND; Williams JP; Smith EB; Bozigian HP; Grigoriadis DE
Prog Med Chem; 2018; 57(1):87-111. PubMed ID: 29680151
[TBL] [Abstract][Full Text] [Related]
2. Valbenazine for the treatment of tardive dyskinesia.
Barquero N
Drugs Today (Barc); 2016 Dec; 52(12):665-672. PubMed ID: 28276538
[TBL] [Abstract][Full Text] [Related]
3. Pharmacologic Characterization of Valbenazine (NBI-98854) and Its Metabolites.
Grigoriadis DE; Smith E; Hoare SRJ; Madan A; Bozigian H
J Pharmacol Exp Ther; 2017 Jun; 361(3):454-461. PubMed ID: 28404690
[TBL] [Abstract][Full Text] [Related]
4. Treatment of Tardive Dyskinesia: A General Overview with Focus on the Vesicular Monoamine Transporter 2 Inhibitors.
Niemann N; Jankovic J
Drugs; 2018 Apr; 78(5):525-541. PubMed ID: 29484607
[TBL] [Abstract][Full Text] [Related]
5. Effects of NBI-98782, a selective vesicular monoamine transporter 2 (VMAT2) inhibitor, on neurotransmitter efflux and phencyclidine-induced locomotor activity: Relevance to tardive dyskinesia and antipsychotic action.
Huang M; He W; Rajagopal L; Kudwa A; Grigoriadis DE; Meltzer HY
Pharmacol Biochem Behav; 2020 Mar; 190():172872. PubMed ID: 32084491
[TBL] [Abstract][Full Text] [Related]
6. Valbenazine in the treatment of tardive dyskinesia.
Witek N; Comella C
Neurodegener Dis Manag; 2019 Apr; 9(2):73-81. PubMed ID: 30724115
[TBL] [Abstract][Full Text] [Related]
7. Valbenazine as the first and only approved treatment for adults with tardive dyskinesia.
Sarva H; Henchcliffe C
Expert Rev Clin Pharmacol; 2018 Mar; 11(3):209-217. PubMed ID: 29338466
[TBL] [Abstract][Full Text] [Related]
8. Tardive dyskinesia: placing vesicular monoamine transporter type 2 (VMAT2) inhibitors into clinical perspective.
Citrome L
Expert Rev Neurother; 2018 Apr; 18(4):323-332. PubMed ID: 29557243
[TBL] [Abstract][Full Text] [Related]
9. VMAT2 Inhibitors for Tardive Dyskinesia-Practice Implications.
Peckham AM; Nicewonder JA
J Pharm Pract; 2019 Aug; 32(4):450-457. PubMed ID: 29455579
[TBL] [Abstract][Full Text] [Related]
10. Valbenazine for the treatment of tardive dyskinesia.
Müller T
Expert Rev Neurother; 2017 Dec; 17(12):1135-1144. PubMed ID: 28971695
[TBL] [Abstract][Full Text] [Related]
11. Comparing pharmacologic mechanism of action for the vesicular monoamine transporter 2 (VMAT2) inhibitors valbenazine and deutetrabenazine in treating tardive dyskinesia: does one have advantages over the other?
Stahl SM
CNS Spectr; 2018 Aug; 23(4):239-247. PubMed ID: 30160230
[TBL] [Abstract][Full Text] [Related]
12. Valbenazine for Tardive Dyskinesia.
Freudenreich O; Remington G
Clin Schizophr Relat Psychoses; 2017; 11(2):113-119. PubMed ID: 28742396
[TBL] [Abstract][Full Text] [Related]
13. Valbenazine: First Global Approval.
Kim ES
Drugs; 2017 Jul; 77(10):1123-1129. PubMed ID: 28578484
[TBL] [Abstract][Full Text] [Related]
14. KINECT 3: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial of Valbenazine for Tardive Dyskinesia.
Hauser RA; Factor SA; Marder SR; Knesevich MA; Ramirez PM; Jimenez R; Burke J; Liang GS; O'Brien CF
Am J Psychiatry; 2017 May; 174(5):476-484. PubMed ID: 28320223
[TBL] [Abstract][Full Text] [Related]
15. Valbenazine for the treatment of tardive dyskinesia.
Seeberger LC; Hauser RA
Expert Opin Pharmacother; 2017 Aug; 18(12):1279-1287. PubMed ID: 28699794
[TBL] [Abstract][Full Text] [Related]
16. Treatment of tardive dyskinesia with tetrabenazine or valbenazine: a systematic review.
Caroff SN; Aggarwal S; Yonan C
J Comp Eff Res; 2018 Feb; 7(2):135-148. PubMed ID: 28965423
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of Valbenazine (NBI-98854) in Treating Subjects with Tardive Dyskinesia and Mood Disorder.
Correll CU; Josiassen RC; Liang GS; Burke J; O'Brien CF
Psychopharmacol Bull; 2017 Aug; 47(3):53-60. PubMed ID: 28839340
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of Valbenazine (NBI-98854) in Treating Subjects with Tardive Dyskinesia and Schizophrenia or Schizoaffective Disorder.
Kane JM; Correll CU; Liang GS; Burke J; O'Brien CF
Psychopharmacol Bull; 2017 Aug; 47(3):69-76. PubMed ID: 28839342
[TBL] [Abstract][Full Text] [Related]
19. Valbenazine and deutetrabenazine: Vesicular monoamine transporter 2 inhibitors for tardive dyskinesia.
Khorassani F; Luther K; Talreja O
Am J Health Syst Pharm; 2020 Jan; 77(3):167-174. PubMed ID: 31974564
[TBL] [Abstract][Full Text] [Related]
20. VMAT2 Inhibitors in Neuropsychiatric Disorders.
Tarakad A; Jimenez-Shahed J
CNS Drugs; 2018 Dec; 32(12):1131-1144. PubMed ID: 30306450
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
